Roche agreed to buy PathAI in a deal structured around $750 million in upfront consideration, aiming to accelerate the use of AI in digital pathology workflows. PathAI supplies technology used by pathology laboratories and biopharma teams to support imaging-based discovery and translational analytics. The acquisition underscores how large diagnostics and pharma groups are consolidating AI capabilities that can be deployed across clinical trial operations and routine pathology settings. For Roche, it also signals continued investment in tools that can improve throughput and decision-making from slide to data. By bringing PathAI in-house, Roche looks positioned to unify model development, validation, and commercialization under a single organizational structure, reducing friction between platform development and customer deployment.